FL-MHPS
15.4.2020 12:02:05 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems’ (MHPS) J-Series gas turbine installed fleet today reached one million hours of commercial operation, nearly double that of similar sized gas turbines from competitors. This gas turbine series — the company’s largest and most advanced — leads the industry with reliable, efficient power generation and flexibility to meet rigid new standards for reduced carbon emissions. Introduced in 2011, the J-Series delivers an industry-leading overall reliability of 99.5% and an efficiency greater than 64%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005220/en/
Forty-three J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
Donald Schubert, Principal at SHL Consulting LLC and former Senior Vice President of Marshes Global Power Practice, said, “MHPS continues to embrace proven technology throughout their gas turbine fleet. The insurability of the operating units remains at an all-time high for MHPS large frame machines.”
In many parts of the world, the J-Series gas turbine frequently replaces retired coal-fired power generation or is installed as an alternative to coal-fired power generation. Compared to the same size coal-fired power plants, one million J-Series operating hours has resulted in CO2 emissions reduction of 270 million tons. This is equivalent to CO2 emissions from 1,346,918 railcars of coal burned.
Ken Kawai, President and CEO of MHPS said, “As we reflect on the important milestone of achieving one million operating hours with our J-Series gas turbine, we know the most important part of that accomplishment is that we ran all those hours with 99.5% reliability. It all started with T-Point, our own combined cycle power plant in Takasago, Japan. Our extreme reliability is not by good luck. It is because we test the durability and reliability of every new technological advancement for 8,000 hours before shipping it to our customers. We have now built a second T-Point, T-Point 2, where our latest advancement, the cutting-edge air-cooled 60 Hz JAC, has just synced to the grid and achieved full load. Step-by-step, we have developed the largest, most reliable and most fuel-efficient gas turbine in the world.”
Recent innovations to the J-Series target further reductions in carbon emissions. Last month the company received an order from the Intermountain Power Agency, in Delta, Utah, for two JAC gas turbines capable of using up to 30% renewable hydrogen fuel. Eventually, these turbines will be capable of using 100% renewable hydrogen fuel. The 30% hydrogen system will reduce carbon emissions by more than 75% compared to the same size coal-fired power plant, and the 100% hydrogen system will eliminate carbon emissions entirely. MHPS is also developing grid-scale renewable hydrogen production and storage through the Advanced Clean Energy Storage (ACES) project in Delta, Utah.
Paul Browning, President and CEO of MHPS Americas and newly appointed Chief Regional Officer for Europe, Africa and the Middle East, said, “Going forward, every gas turbine MHPS sells globally will have renewable hydrogen fuel capability. This allows our customers to purchase a natural gas power plant today, and convert it over time into a renewable energy storage facility. This gives plant operators flexibility now and into the future to choose what mix of natural gas power generation and renewable energy storage best meets the needs of their electrical grids. We are providing the power generation and storage solutions that enable our customers to combat climate change and advance human prosperity. This is a Change in Power.”
About Mitsubishi Hitachi Power Systems Americas, Inc. Mitsubishi Hitachi Power Systems Americas, Inc. (MHPS Americas), headquartered in Lake Mary, Florida, employs more than 2,000 power generation and energy storage experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity. MHPS Americas’ expertise includes natural gas, steam, aero-derivative, geothermal, and distributed renewable power generation technologies and services, along with renewable hydrogen and battery energy storage systems, environmental control systems solutions, and digital solutions enabling autonomous operations and maintenance of power assets throughout North and South America. MHPS Americas is a subsidiary of Mitsubishi Hitachi Power Systems (MHPS), a joint venture between Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in power generation systems. Learn more about MHPS by visiting www.changeinpower.com . |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom